MA43709A - Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations - Google Patents

Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations

Info

Publication number
MA43709A
MA43709A MA043709A MA43709A MA43709A MA 43709 A MA43709 A MA 43709A MA 043709 A MA043709 A MA 043709A MA 43709 A MA43709 A MA 43709A MA 43709 A MA43709 A MA 43709A
Authority
MA
Morocco
Prior art keywords
empagliflozin
pharmaceutical composition
composition consisting
pharmaceutical
composition
Prior art date
Application number
MA043709A
Other languages
English (en)
Inventor
Uli Broedl
Afshin Salsali
Hans-Juergen Woerle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA43709A publication Critical patent/MA43709A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043709A 2016-03-16 2017-03-13 Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations MA43709A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309008P 2016-03-16 2016-03-16
US201662420062P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
MA43709A true MA43709A (fr) 2018-11-28

Family

ID=58267120

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043709A MA43709A (fr) 2016-03-16 2017-03-13 Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations

Country Status (13)

Country Link
US (6) US20170266152A1 (fr)
EP (1) EP3429595A1 (fr)
JP (4) JP7161405B2 (fr)
KR (6) KR20230111262A (fr)
CN (4) CN118286238A (fr)
AU (3) AU2017233889B2 (fr)
BR (1) BR112018016001A2 (fr)
CA (1) CA3017992A1 (fr)
CL (1) CL2018002532A1 (fr)
MA (1) MA43709A (fr)
MX (4) MX2018011088A (fr)
PH (2) PH12021552046A1 (fr)
WO (1) WO2017157816A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ­２ 억제제
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CA2812016A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
WO2018087132A1 (fr) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Composition pharmaceutique, méthodes de traitement et leurs utilisations
EP3691650A1 (fr) * 2017-10-02 2020-08-12 Poxel Méthodes de traitement d'une insuffisance cardiaque avec fraction d'éjection préservée
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (fr) 2018-06-14 2019-12-19 Poxel Comprime pellicule comprenant un derive de triazine destine a etre utilise dans le traitement du diabete
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
CN109846898A (zh) * 2019-02-01 2019-06-07 同济大学 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
IT201900006624A1 (it) * 2019-05-08 2020-11-08 Moret Giannino Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
BR112020008705A2 (pt) * 2019-08-30 2022-03-22 Astrazeneca Ab Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
JP7659783B2 (ja) * 2019-09-13 2025-04-10 国立大学法人富山大学 急性心不全における体液貯留改善薬
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
US20240398845A1 (en) 2021-07-28 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
ES2596202T3 (es) * 2009-09-30 2017-01-05 Boehringer Ingelheim International Gmbh Método para la preparación de una forma cristalina de 1-cloro-4-(ß-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) * 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US20140303097A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) * 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (fr) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
PL2986304T3 (pl) * 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania

Also Published As

Publication number Publication date
AU2024216447B2 (en) 2026-06-11
CN118903166A (zh) 2024-11-08
AU2017233889B2 (en) 2022-07-07
CA3017992A1 (fr) 2017-09-21
KR20240095321A (ko) 2024-06-25
US20220211659A1 (en) 2022-07-07
MX2022008491A (es) 2022-08-02
AU2017233889A1 (en) 2018-08-09
KR20180122004A (ko) 2018-11-09
JP2024083347A (ja) 2024-06-21
JP7161405B2 (ja) 2022-10-26
US20170266152A1 (en) 2017-09-21
PH12018501969A1 (en) 2019-06-17
JP2023001136A (ja) 2023-01-04
JP7454531B2 (ja) 2024-03-22
JP7843308B2 (ja) 2026-04-09
KR20250161667A (ko) 2025-11-17
US20180318251A1 (en) 2018-11-08
US20250073200A1 (en) 2025-03-06
KR20230028565A (ko) 2023-02-28
AU2022246392B2 (en) 2024-09-19
JP2019508453A (ja) 2019-03-28
KR20230028568A (ko) 2023-02-28
MX2024005626A (es) 2024-05-24
US20210059974A1 (en) 2021-03-04
KR20230111262A (ko) 2023-07-25
CN118286237A (zh) 2024-07-05
AU2024216447A1 (en) 2024-09-19
EP3429595A1 (fr) 2019-01-23
MX2018011088A (es) 2018-11-22
AU2022246392A1 (en) 2022-10-27
PH12021552046A1 (en) 2022-06-27
CN118286238A (zh) 2024-07-05
WO2017157816A1 (fr) 2017-09-21
CL2018002532A1 (es) 2019-01-04
CN109069525A (zh) 2018-12-21
BR112018016001A2 (en) 2018-12-18
US20190350894A1 (en) 2019-11-21
JP2021181461A (ja) 2021-11-25
MX2021010329A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
EP3675863A4 (fr) Composition pharmaceutique comprenant de la sépiaptérine et ses utilisations
EP3691657A4 (fr) Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
EP3434285A4 (fr) Composition pharmaceutique et ses utilisations
EP3370770A4 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
EP3500255A4 (fr) Compositions pharmaceutiques ophtalmiques et utilisations associées
EP3603620A4 (fr) Composition de liposome et composition pharmaceutique
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
EP3307766A4 (fr) Protéine d'interleukine-7 modifiée et ses utilisations
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3678666A4 (fr) Activateur d'akt3 spécifique et ses utilisations
MA46742A (fr) Composition pharmaceutique, méthodes de traitement et leurs utilisations
EP3307772A4 (fr) Anticorps spécifiques de tgf-bêta 3 et procédés et utilisations associés
EP3412660A4 (fr) Dérivé de sulfonamide et composition pharmaceutique le contenant
EP3685828A4 (fr) Composition pharmaceutique ophtalmique, trousse ophtalmique et application pharmaceutique associée
MA49726A (fr) Formulation d'anticorps anti-cgrp
EP3412292A4 (fr) Utilisation de méthoxatine, d'un dérivé et/ou d'un sel de cette dernière contre le syndrome de gougerot-sjögren, et composition pharmaceutique
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
EP3675874A4 (fr) Composition pharmaceutique pour le traitement des chéloïdes et ses utilisations
EP3777866A4 (fr) Composition pharmaceutique et application de cette dernière
EP3496748A4 (fr) Anticorps anti-o2 et utilisations associées
EP3509627A4 (fr) Inhibiteurs de l'histone déméthylase-1 spécifiques de la lysine et leurs utilisations
MA47516A (fr) Composition pharmaceutique